Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Ixempra
Ixabepilone is a semi-synthetic epothilone B analog, a microtubule-stabilizing agent used in the treatment of advanced or metastatic breast cancer. It belongs to the class of chemotherapeutic agents known as taxanes, although it is not structurally related to taxanes. Ixabepilone works by binding to microtubules, inhibiting their depolymerization, and ultimately disrupting cell division and leading to cell death. It is typically used in patients whose cancer has progressed after treatment with other chemotherapy regimens, including an anthracycline and a taxane.
For the treatment of metastatic or locally advanced breast cancer resistant to other chemotherapies.
Outcome:
Increased ixabepilone toxicity
Mechanism:
Reduced ixabepilone metabolism
Outcome:
May increase ixabepilone toxicity
Mechanism:
Reduced ixabepilone metabolism
Outcome:
May slightly reduce ixabepilone absorption
Mechanism:
Changes in gastric pH
Most likely new formulation: Liposomal ixabepilone for improved delivery and reduced toxicity (2026, 30% confidence).
Based on current usage trends and clinical trial data, there is a low probability ( <10%) of ixabepilone being withdrawn from the market in the next 5 years.
Antineoplastic, Microtubule Stabilizing Agent, Epothilone Analog
Epothilone